Along these lines, in patients with lung cancer who have tumors that have become resistant to EGFR inhibitors, EMT induction results in increased expression of the cell surface protein CD70, opening up the possibility to use new interventions involving CAR-NK or antibody–drug conjugates that specifically guide therapeutic agents to CD70-expressing cells in order to eliminate drug-resistant cells that have undergone EMT [197]. The gene discussed is CD70; the disease is lung carcinoma.